Has an owner of Roche’s stock read the article: “Vivus: Qnexa is Not Guaranteed Approval. Remember Provenge? The article addresses the weight loss/obesity marketplace. Is anyone on this blog concerned about the effect Chromadex could have on the entire weight loss/obesity drug market as a whole? Do you think Roche would be adversely affected by potential positive results to be released in the next few weeks? From what I understand, Roche is a direct competitor.